A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".

SJRES141 is a joint resolution to disapprove the BCFP's withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt." This means the resolution seeks to re-establish the original rule, which restricts how medical debt can be collected. The immediate impact is increased regulatory burden on debt collectors and financial institutions that purchase or service medical debt. Healthcare providers will also face challenges in collecting outstanding medical bills, potentially impacting their revenue cycles. The money trail for this resolution is indirect. It does not appropriate funds but rather dictates regulatory enforcement. Financial institutions involved in debt collection, such as JPMorgan Chase ($JPM), Bank of America ($BAC), Wells Fargo ($WFC), Discover Financial Services ($DFS), Capital One ($COF), and Citigroup ($C), will incur higher compliance costs and may see reduced recovery rates on medical debt portfolios. Healthcare providers like HCA Healthcare ($HCA) and Universal Health Services ($UHS), and health insurers like Centene ($CNC) and UnitedHealth Group ($UNH) that manage claims and patient billing, will face more stringent collection environments, potentially leading to higher bad debt expenses. Historically, increased regulation on debt collection has led to higher operational costs for financial services and collection agencies. For example, when the original Regulation F was implemented in 2021, collection agencies reported increased compliance expenditures. While specific market data on the impact of Regulation F on medical debt collection is limited due to its recent nature, similar regulatory tightening in other debt categories has historically led to a 2-5% increase in operational costs for collection firms and a slight decrease in recovery rates for creditors. The Consumer Financial Protection Bureau's actions in 2022 to remove medical debt from credit reports also signaled a trend towards consumer protection, which generally pressures debt collectors and creditors. Specific winners are consumers with medical debt, as collection practices will become more restricted. Specific losers include financial institutions engaged in debt purchasing and collection, such as JPMorgan Chase ($JPM), Bank of America ($BAC), Wells Fargo ($WFC), Discover Financial Services ($DFS), Capital One ($COF), and Citigroup ($C), due to increased compliance costs and reduced recovery rates. Healthcare providers like HCA Healthcare ($HCA) and Universal Health Services ($UHS) will also experience negative impacts on their revenue cycles. The resolution is currently in the committee stage. If it passes the Senate and House, it would then go to the President. Given the sponsor, Senator Warnock (D-GA), the resolution aligns with a consumer-friendly regulatory stance, suggesting potential for movement.